PATOU GARY 4
4 · Xenon Pharmaceuticals Inc. · Filed Jun 8, 2026
Research Summary
AI-generated summary of this filing
Xenon (XENE) Director Gary Patou Sells 1,322 Shares
What Happened
Gary Patou, a director of Xenon Pharmaceuticals (XENE), sold 1,322 shares on June 5, 2026. The shares were disposed at $53.14 per share for a total transaction value of $70,251. The sale was reported on a Form 4 filed June 8, 2026.
Key Details
- Transaction type: Sale (open-market), code S
- Date of transaction: 2026-06-05
- Price per share: $53.14; Shares sold: 1,322; Total proceeds: $70,251
- Shares owned after transaction: Not specified in the provided filing excerpt
- Footnotes:
- F1: Sale effected pursuant to a Rule 10b5-1 trading plan adopted Aug 17, 2025 to satisfy tax obligations from RSUs granted June 5, 2025.
- F2: Transaction executed by/through the Patou Family Trust (Gary & Karen Barbara Patou, Trustee).
- Filing: Form 4 filed 2026-06-08; no late-filing indication in the summary provided.
Context
This sale was made under a pre-established 10b5-1 plan to cover tax obligations tied to RSU vesting, which commonly explains routine insider sales and should not be read on its own as a signal of management sentiment. For retail investors, purchases by insiders typically carry more emphasis than routine sales; always consider insider trades alongside company fundamentals and broader market activity.
Insider Transaction Report
Form 4
PATOU GARY
Director
Transactions
- Sale
Common Shares
[F1]2026-06-05$53.14/sh−1,322$70,251→ 24,896 total
Holdings
- 4,902(indirect: See Note)
Common Shares
[F2]
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person on August 17, 2025, solely to satisfy income tax obligations related to the vesting of RSUs granted on June 5, 2025.
- [F2]By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.
Signature
/s/ Nathaniel Adams, Attorney-in-fact|2026-06-08